These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35380100)

  • 1. Assessing the transition of COVID-19 burden towards the young population while vaccines are rolled out in China.
    Cai J; Yang J; Deng X; Peng C; Chen X; Wu Q; Liu H; Zhang J; Zheng W; Zou J; Zhao Z; Ajelli M; Yu H
    Emerg Microbes Infect; 2022 Dec; 11(1):1205-1214. PubMed ID: 35380100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Technical guidelines for seasonal influenza vaccination in China (2021-2022)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) , Influenza Vaccination TWG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1722-1749. PubMed ID: 34814607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitigating the SARS-CoV-2 Delta disease burden in Australia by non-pharmaceutical interventions and vaccinating children: a modelling analysis.
    Milne GJ; Carrivick J; Whyatt D
    BMC Med; 2022 Feb; 20(1):80. PubMed ID: 35177062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021.
    Griffin JB; Haddix M; Danza P; Fisher R; Koo TH; Traub E; Gounder P; Jarashow C; Balter S
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1170-1176. PubMed ID: 34437525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Technical guidelines for seasonal influenza vaccination in China (2020-2021)].
    National Immunization Advisory Committee Technical Working Group
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Oct; 54(10):1035-1059. PubMed ID: 33131228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can we get out of the COVID pandemic without adequate vaccination coverage in the pediatric population?
    Esposito S; Giordano R; Paini G; Puntoni M; Principi N; Caminiti C
    Ital J Pediatr; 2022 Aug; 48(1):150. PubMed ID: 35986340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Who should be prioritized for COVID-19 vaccination in China? A descriptive study.
    Yang J; Zheng W; Shi H; Yan X; Dong K; You Q; Zhong G; Gong H; Chen Z; Jit M; Viboud C; Ajelli M; Yu H
    BMC Med; 2021 Feb; 19(1):45. PubMed ID: 33563270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A scenario modelling analysis to anticipate the impact of COVID-19 vaccination in adolescents and children on disease outcomes in the Netherlands, summer 2021.
    Ainslie KEC; Backer JA; de Boer PT; van Hoek AJ; Klinkenberg D; Korthals Altes H; Leung KY; de Melker H; Miura F; Wallinga J
    Euro Surveill; 2022 Nov; 27(44):. PubMed ID: 36330824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and Vaccination Coverage.
    Christie A; Brooks JT; Hicks LA; Sauber-Schatz EK; Yoder JS; Honein MA;
    MMWR Morb Mortal Wkly Rep; 2021 Jul; 70(30):1044-1047. PubMed ID: 34324480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021.
    Mendes D; Chapman R; Gal P; Atwell J; Nguyen JL; Hamson L; Di Fusco M; Czudek C; Yang J
    J Med Econ; 2022; 25(1):1039-1050. PubMed ID: 36097853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.
    Li XN; Huang Y; Wang W; Jing QL; Zhang CH; Qin PZ; Guan WJ; Gan L; Li YL; Liu WH; Dong H; Miao YT; Fan SJ; Zhang ZB; Zhang DM; Zhong NS
    Emerg Microbes Infect; 2021 Dec; 10(1):1751-1759. PubMed ID: 34396940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrease in COVID-19 adverse outcomes in adults during the Delta and Omicron SARS-CoV-2 waves, after vaccination in Mexico.
    Domínguez-Ramírez L; Solis-Tejeda I; Ayon-Aguilar J; Mayoral-Ortiz A; Sosa-Jurado F; Pelayo R; Santos-López G; Cortes-Hernandez P
    Front Public Health; 2022; 10():1010256. PubMed ID: 36176536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality.
    Patel MD; Rosenstrom E; Ivy JS; Mayorga ME; Keskinocak P; Boyce RM; Hassmiller Lich K; Smith RL; Johnson KT; Delamater PL; Swann JL
    JAMA Netw Open; 2021 Jun; 4(6):e2110782. PubMed ID: 34061203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia.
    McBryde ES; Meehan MT; Caldwell JM; Adekunle AI; Ogunlade ST; Kuddus MA; Ragonnet R; Jayasundara P; Trauer JM; Cope RC
    Med J Aust; 2021 Nov; 215(9):427-432. PubMed ID: 34477236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An assessment of the vaccination of school-aged children in England against SARS-CoV-2.
    Keeling MJ; Moore SE
    BMC Med; 2022 May; 20(1):196. PubMed ID: 35581585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-Varying Susceptibility to the Delta Variant (B.1.617.2) of SARS-CoV-2.
    Chun JY; Jeong H; Kim Y
    JAMA Netw Open; 2022 Mar; 5(3):e223064. PubMed ID: 35302625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 Vaccination and Incidence of Pediatric SARS-CoV-2 Infection and Hospitalization.
    Head JR; Collender PA; León TM; White LA; Sud SR; Camponuri SK; Lee V; Lewnard JA; Remais JV
    JAMA Netw Open; 2024 Apr; 7(4):e247822. PubMed ID: 38652476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simulated Identification of Silent COVID-19 Infections Among Children and Estimated Future Infection Rates With Vaccination.
    Moghadas SM; Fitzpatrick MC; Shoukat A; Zhang K; Galvani AP
    JAMA Netw Open; 2021 Apr; 4(4):e217097. PubMed ID: 33890990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.